Retractable Technologies Inc

Análisis de la acción Retractable Technologies Inc (RVP)

$0.569

+0.003 (+0.60%)Al cierre

Loading chart…
Máximo
0.582
Apertura
0.578
Precio medio ponderado por volumen
0.57
Volumen
51.72K
Capitalización
32.63M
Mínimo
0.562
Importe
29.53K
EV/EBITDA, TTM
0.00

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors.

retractable.com

Análisis de IA of Retractable Technologies Inc (RVP)

Vender

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

Métricas de valoración

El PER previsto actual de Retractable Technologies Inc (RVP) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para RVP

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%RVP

$0.71

Precio del escenario

B

Base

Base · 50%RVP

$0.66

Precio del escenario

B

Bajista

Bajista · 25%RVP

$0.57

Precio del escenario

Preguntas frecuentes sobre RVP, respondidas por Alphio AI

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar